The study titled Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice and published in Hormone and Metabolic Research indicates that 58% of patients reported side effects mostly concerning the gastrointestinal tract. In addition, more than 20% of the participants quit the drug because of intolerable side effects. This study certainly put Novo Nordisk on risk of bowel injuries associated with the use of Ozempic
The experience at each is not the same
GLP-1RAs may be the game changers for CKD in the next decades
When testosterone levels are optimised through treatment for confirmed hypogonadism (low testosterone), many patients report improvements in mood, reduced irritability, and enhanced emotional wellbeing
Nutrition (Burbank, Los Angeles County, Calif.), 57 , 133140
InfiniWell BPC-Lx Pro Technology: lipid-based oral fine mist Why it is plausible Buccal delivery can avoid part of the GI pathway